α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

Parkinson’s disease (PD) is a prevalent neurodegenerative disease with no approved disease-modifying therapies. Multiplications, mutations, and single nucleotide polymorphisms in the SNCA gene, encoding α-synuclein (aSyn) protein, either cause or increase risk for PD. Intracellular accumulations of...

Full description

Bibliographic Details
Main Authors: Tracy A. Cole, Hien Zhao, Timothy J. Collier, Ivette Sandoval, Caryl E. Sortwell, Kathy Steece-Collier, Brian F. Daley, Alix Booms, Jack Lipton, Mackenzie Welch, Melissa Berman, Luke Jandreski, Danielle Graham, Andreas Weihofen, Stephanie Celano, Emily Schulz, Allyson Cole-Strauss, Esteban Luna, Duc Quach, Apoorva Mohan, C. Frank Bennett, Eric E. Swayze, Holly B. Kordasiewicz, Kelvin C. Luk, Katrina L. Paumier
Format: Article
Language:English
Published: American Society for Clinical investigation 2021-03-01
Series:JCI Insight
Subjects:
Neuroscience
Therapeutics
Online Access:https://doi.org/10.1172/jci.insight.135633

Internet

https://doi.org/10.1172/jci.insight.135633

Similar Items